Western Pharma Companies Pivot to India Amid China Concerns

Despite Quality Concerns, Indian Drug Manufacturers See Increased Interest and Strong Growth

Western pharmaceutical companies are reducing their reliance on Chinese contractors for drug production and turning to India, despite concerns over quality and oversight.
Indian Contract Development and Manufacturing Organisations (CDMOs) have seen increased interest and requests from Western companies, leading to strong profit growth.
India's CDMO industry is expected to grow at a rate of more than 11% annually over the next five years, compared to China's estimated growth of 9.6%.
Despite the shift, concerns over lax oversight in India persist, with calls for Indian CDMOs to improve their quality standards to match Western and Chinese ones.
Major Indian CDMOs are expanding their manufacturing capacity to meet the growing demand.